Gentamicin blood levels: ordered too soon and too often.

Area of Science:

• Pharmacokinetics and Pharmacodynamics
• Infectious Disease Management
• Clinical Pharmacy

Background:

• Gentamicin blood levels (GBLs) are frequently monitored to optimize therapy and minimize toxicity.
• Current guidelines and practices for GBL monitoring may lead to overuse and increased healthcare costs.

Purpose of the Study:

• To evaluate the relationship between gentamicin blood levels, clinical course, and patient outcomes.
• To determine if current GBL monitoring practices are cost-effective and safe.

Main Methods:

• Retrospective review of 100 consecutive patients who underwent GBL measurement.
• Analysis of treatment duration, reasons for discontinuation, clinical outcomes, and renal function.

Main Results:

• A significant portion of patients discontinued gentamicin early due to negative cultures or alternative antibiotic suitability.
• Many patients achieved good outcomes despite sub-therapeutic peak or trough GBLs, often with combination therapy.
• Nephrotoxicity was infrequent, even in patients with high GBLs and normal renal function.

Conclusions:

• Current GBL monitoring practices may lead to wasteful overuse.
• Delaying GBL measurements until 72-96 hours, pending culture results, can reduce costs without compromising patient outcomes.
• Exceptions for monitoring include patients with decreased renal function, gram-negative sepsis, leukopenia, or severe burns.